临床研究结果显示,肌层浸润性膀胱癌(MIBC)在行手术切除膀胱及盆腔淋巴结清扫后,癌灶局限且淋巴结转移阴性者其5年总体生存率可达80%以上,但若发生膀胱壁外浸润则降低至40%~50%,若发生淋巴结转移则降至15%~30%;而复发则多与微小转移灶有关[1]。因此,将化疗作为膀胱全切术的辅助性治疗,可发挥控制肿瘤转移、减少复发和进展风险及改善预后的作用。实际上,在MIBC的治疗中,化疗 Clinical studies have shown that the 5-year overall survival rate of myometrial invasive bladder cancer (MIBC) after surgical removal of the bladder and pelvic lymph nodes is limited and the lymph node metastasis is negative. However, if the bladder wall External infiltration decreased to 40% to 50%, if the occurrence of lymph node metastasis was reduced to 15% to 30%; and recurrence and more are associated with micrometastases [1]. Therefore, the chemotherapy as an adjuvant treatment of bladder total excision can play a role in controlling tumor metastasis, reduce the risk of recurrence and progression and improve the prognosis. In fact, in the treatment of MIBC, chemotherapy